ModifiedUnitedHealthcarePolicy N/A

Gastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for Idaho Only)

Defines medical necessity and limitations for multiplex PCR gastrointestinal pathogen panels for evaluation of infectious diarrhea for Idaho members (including Idaho Medicaid Plus).

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for Idaho Only)

Policy CodePolicy N/A

Change TypeMaterial coverage updateadded not medically necessary threshold

Effective DateN/A

Next Review DateN/A

Key ActionDo not request coverage for multiplex PCR GI pathogen panels with more than 11 targets; ensure medical record documents history, exam, and pertinent test results to support necessity.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate multiplex PCR panel testing of gastrointestinal pathogens > 11 targets is unproven and not medically necessary due to insufficient evidence of efficacy.

Added explicit medical record documentation requirements to support medical necessity for requested services.

Updated Description of Services, Clinical Evidence, and References sections to reflect current information.

Removed reference link to the guidelines titled Medical Records Documentation Used for Reviews.

≤5covered when performed with blood cultures for specific presentations

≤11covered for persistent diarrhea with risk factors

>11not medically necessary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Idahogeographic applicability

IDSA 2017guideline referenced

Coverage Criteria

Medically Necessary Indications

Covered when ANY of the following covered scenarios are met (panel size-specific):

3-5 target panel coverage: Multiplex PCR panel testing including up to five targets when performed as part of an evaluation that includes blood cultures for an individual with any one of: (1) diarrhea for more than seven days; OR (2) diarrhea with at least one of: fever, bloody or mucoid stools, severe abdominal cramping or tenderness, signs of sepsis; OR (3) suspected enteric fever in an individual with recent travel to an endemic region or who has consumed food prepared by people with recent endemic exposure.<=5 targets

covers CPT 87505

6-11 target panel coverage for persistent diarrhea: Multiplex PCR panel testing including up to 11 targets for the evaluation of persistent diarrhea in an individual with any one of: (1) at risk for Clostridium difficile colitis AND diarrhea for more than seven days; OR (2) at risk for Clostridium difficile colitis AND diarrhea with at least one of: fever, bloody or mucoid stools, severe abdominal cramping or tenderness, signs of sepsis.6-11 targets

covers CPT 87506

Unproven / Not Medically Necessary

Not medically necessary: Multiplex PCR panel testing of gastrointestinal pathogens for all other indications not listed above; and multiplex PCR panels with more than 11 targets.>11 targets or unspecified

includes CPT 87507 and 0369U

Coverage rationale and guideline context

Policy-level coverage rationale and professional guidance context

Coverage limitation for high-multiplex panels: Multiplex PCR panel testing of gastrointestinal pathogens with more than 11 targets is considered unproven and not medically necessary due to insufficient evidence of efficacy.>11 targets

Added to policy 05/01/2026

When testing is recommended by guidelines: Culture-independent multiplex molecular tests are recommended by professional societies (e.g., IDSA, ACG) in specific clinical contexts — moderate-to-severe, bloody, or febrile diarrhea; nosocomial or persistent diarrhea; suspected enteric fever; or in immunocompromised hosts — and when results are expected to change management. For C. difficile, guidelines recommend a two-step algorithm (sensitive plus specific test) because NAAT alone cannot distinguish colonization from active infection. When available, culture-independent tests may be used adjunctively to culture and may require parallel culture for pathogens (e.g., Salmonella) given variable sensitivity.clinical indications per guideline

Multiplex PCR gastrointestinal pathogen panel testing performed for indications other than those specifically listed in the policy is considered unproven and not medically necessary. Requests for testing outside the covered clinical scenarios (for example, screening or routine testing without the specified clinical features) may be denied.

Multiplex PCR panels that include more than 11 targets are excluded from coverage and are considered unproven and not medically necessary due to insufficient evidence of clinical benefit.

Multiplex PCR assays that detect more than 11 targets (for example, CPT code 87507 and assays such as 0369U) are considered not medically necessary because there is insufficient evidence demonstrating improved efficacy or clinical utility for panels of this size.

Multiplex PCR panel testing of gastrointestinal pathogens with greater than 11 targets is designated unproven and not medically necessary due to insufficient evidence of efficacy; such requests are expected to be denied unless documentation can clearly justify medical necessity per policy.

Coding

Referenced HCPCS/othermixed

0369U

Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique.

Referenced CPT CodesCPT

87505	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets.
87506	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets.
87507	Infectious agent detection by nucleic acid (DNA or RNA); gastrointestinal pathogen (e.g., Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets.

Panel target count threshold

Panel target count threshold> 11 targets

Not medically necessary examplesIncludes panels billed as CPT 87507 (12-25 targets) and HCPCS 0369U (31 targets plus resistance genes)

Policy actionRequests for multiplex PCR GI pathogen panels >11 targets are considered unproven and not medically necessary and may be denied

Provider Actions & Requirements

Billing Rule

Panel size determines coverage

Panel size determines coverage. Multiplex PCR gastrointestinal pathogen panels are covered only up to certain panel sizes depending on CPT/HCPCS coding and the clinical indication: panels that detect 3–5 targets (CPT 87505) and up to 11 targets (CPT 87506) may be considered medically necessary when clinical criteria are met; panels > 11 targets (e.g., CPT 87507 for 12–25 targets and comprehensive assays such as 0369U) are considered unproven and not medically necessary.

CPT 87505: 3–5 targets — coverage possible when clinical criteria met
CPT 87506: 6–11 targets — coverage possible for specified persistent/presentations
CPT 87507 and 0369U: >11 targets — considered not medically necessary

Prior Authorization

Prior authorization for >11-target panels

Background

Acute gastrointestinal infections have varied etiologies including bacterial, viral, and parasitic pathogens. Many cases of acute, non-inflammatory diarrhea are self-limited and do not require extensive testing. Culture-independent, nucleic acid amplification-based multiplex assays can increase detection sensitivity and speed compared with traditional culture and are most clinically useful in moderate-to-severe, bloody, febrile, nosocomial, persistent, or immunocompromised presentations where results are likely to change management.

Definitions

Multiplex PCR gastrointestinal pathogen panel — definition

DefinitionAssay detecting multiple bacterial, viral, and/or parasitic enteric pathogens simultaneously using nucleic acid amplification (multiplex PCR)

PurposeUsed to identify etiologies of moderate-to-severe, bloody, febrile, nosocomial, or persistent diarrheal illnesses and in immunocompromised patients

LimitationsViral-only components often have limited clinical usefulness except for immunocompromised patients or infection-control purposes

Billing codes for GI pathogen panels

CPT 87505Infectious agent detection by nucleic acid; gastrointestinal pathogen, multiplex, 3-5 targets

CPT 87506Infectious agent detection by nucleic acid; gastrointestinal pathogen, multiplex, 6-11 targets

Policy Summary

PayerUnitedHealthcare

PolicyGastrointestinal Pathogen Nucleic Acid Detection Panel Testing for Infectious Diarrhea (for Idaho Only)

Policy CodePolicy N/A

Change TypeMaterial coverage updateadded not medically necessary threshold

Effective DateN/A

Next Review DateN/A

Key ActionDo not request coverage for multiplex PCR GI pathogen panels with more than 11 targets; ensure medical record documents history, exam, and pertinent test results to support necessity.

SourceLink

On This Page

Prior authorization may be required and requests for panels > 11 targets are subject to review and are at risk for denial because these large multiplex assays are designated unproven and not medically necessary.

Requests for panels > 11 targets (e.g., CPT 87507, 0369U) may require prior authorization
Such requests are subject to denial as not medically necessary per policy

Denial Risk

Excessively Large Panels

Excessively large panels (>11 targets) are considered not medically necessary and may be denied. Providers should order the smallest panel adequate to answer the clinical question and avoid comprehensive assays that include numerous targets of unclear clinical utility.

CPT 87507 (12–25 targets) — not medically necessary
0369U (31 targets + resistance genes) — not medically necessary

Documentation Required

Medical Record Documentation

The patient's medical record must contain documentation that fully supports the medical necessity for the requested services. This includes relevant medical history, physical examination findings, and results of pertinent diagnostic tests or procedures. Documentation should be legible, maintained in the medical record, and made available upon request; failure to provide adequate documentation may result in denial.

Include relevant history (e.g., duration of diarrhea, travel history, exposures)
Include physical exam findings (e.g., fever, abdominal tenderness, signs of sepsis)
Include prior diagnostic results (e.g., blood cultures, C. difficile testing) supporting the need for multiplex testing

Note

Clinical-criteria ordering expectation

Order testing in accordance with established clinical criteria (for example, the IDSA 2017 recommendations) to limit testing to patients most likely to benefit. Following clinical criteria reduces unnecessary testing and preserves clinical yield.

Follow IDSA criteria: test patients with fever, abdominal pain, bloody stool, immunocompromise, or other indications listed in policy
Adhering to criteria can reduce testing volume without significantly reducing clinical yield

CPT 87507Infectious agent detection by nucleic acid; gastrointestinal pathogen, multiplex, 12-25 targets (considered not medically necessary when >11 targets)

HCPCS 0369UInfectious agent detection by nucleic acid; gastrointestinal pathogens, 31 organisms and identification of 21 antibiotic-resistance genes

Culture-independent multiplex molecular tests

DefinitionCulture-independent multiplex molecular tests: NAAT-based panels that detect multiple GI pathogens from a single specimen without requiring traditional culture methods

Clinical recommendationIDSA and ACG recommend culture-independent methods for bacterial pathogen detection in selected clinical contexts (moderate-to-severe, bloody, febrile, nosocomial, persistent diarrhea, immunocompromised)

Performance notesThese methods generally offer greater sensitivity and faster turnaround than culture but may detect nonviable organisms and are not tests of cure

C. difficile: two-step testing algorithm

Two-step algorithmUse both a highly sensitive and a highly specific testing modality to distinguish C. difficile colonization from active infection because NAAT alone cannot distinguish colonization from infection

Guideline sourceACG 2021 recommends inclusion of both sensitive and specific tests in CDI algorithms

Clinical implicationNAAT-only testing may over-diagnose C. difficile and should be interpreted in clinical context or used as part of a two-step algorithm